- Home
- TRVI vs PRQR Comparison
TRVI vs PRQR Comparison
Compare TRVI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- PRQR
- Stock Information
- Founded
- TRVI 2011
- PRQR 2012
- Country
- TRVI United States
- PRQR Netherlands
- Employees
- TRVI N/A
- PRQR N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- TRVI Health Care
- PRQR Health Care
- Exchange
- TRVI Nasdaq
- PRQR Nasdaq
- Market Cap
- TRVI 363.7M
- PRQR 309.5M
- IPO Year
- TRVI 2019
- PRQR 2014
- Fundamental
- Price
- TRVI $4.60
- PRQR $2.56
- Analyst Decision
- TRVI Strong Buy
- PRQR Strong Buy
- Analyst Count
- TRVI 8
- PRQR 6
- Target Price
- TRVI $9.31
- PRQR $8.17
- AVG Volume (30 Days)
- TRVI 739.7K
- PRQR 286.6K
- Earning Date
- TRVI 03-19-2025
- PRQR 03-12-2025
- Dividend Yield
- TRVI N/A
- PRQR N/A
- EPS Growth
- TRVI N/A
- PRQR N/A
- EPS
- TRVI N/A
- PRQR N/A
- Revenue
- TRVI N/A
- PRQR $20,506,357.00
- Revenue This Year
- TRVI N/A
- PRQR $210.18
- Revenue Next Year
- TRVI N/A
- PRQR $33.25
- P/E Ratio
- TRVI N/A
- PRQR N/A
- Revenue Growth
- TRVI N/A
- PRQR 306.68
- 52 Week Low
- TRVI $2.30
- PRQR $1.61
- 52 Week High
- TRVI $5.05
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- TRVI 62.80
- PRQR 56.93
- Support Level
- TRVI $3.93
- PRQR $2.47
- Resistance Level
- TRVI $4.14
- PRQR $2.67
- Average True Range (ATR)
- TRVI 0.29
- PRQR 0.18
- MACD
- TRVI 0.06
- PRQR 0.07
- Stochastic Oscillator
- TRVI 64.82
- PRQR 83.58
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.